Clinical quantification of the integrin αvβ6 by [

Biomarker Clinical study Idiopathic pulmonary fibrosis PET Pulmonary fibrosis [18F]FB-A20FMDV2 PET/CT αvβ6 integrin

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
04 2020
Historique:
received: 25 07 2019
accepted: 16 10 2019
pubmed: 10 12 2019
medline: 15 5 2021
entrez: 10 12 2019
Statut: ppublish

Résumé

The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [ [ A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V Lung uptake of [

Identifiants

pubmed: 31814068
doi: 10.1007/s00259-019-04586-z
pii: 10.1007/s00259-019-04586-z
pmc: PMC7075837
doi:

Substances chimiques

Antigens, Neoplasm 0
Integrins 0
integrin alphavbeta6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

967-979

Subventions

Organisme : HSRD VA
ID : CDA 13-017
Pays : United States
Organisme : Department of Health
ID : CS-2013-13-017
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901226
Pays : United Kingdom

Références

Cancer Res. 2007 Aug 15;67(16):7833-40
pubmed: 17699789
J Gen Virol. 2005 Oct;86(Pt 10):2769-2780
pubmed: 16186231
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2238-46
pubmed: 21874321
Am J Respir Cell Mol Biol. 2016 Dec;55(6):759-766
pubmed: 27603223
J Nucl Med. 2013 Jul;54(7):1101-5
pubmed: 23670900
FEBS Lett. 2002 Jan 30;511(1-3):65-8
pubmed: 11821050
Thorax. 2014 Mar;69(3):216-22
pubmed: 24127020
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Cell. 1999 Feb 5;96(3):319-28
pubmed: 10025398
Mol Imaging. 2009 Mar-Apr;8(2):111-21
pubmed: 19397856
Biometrics. 1997 Sep;53(3):983-97
pubmed: 9333350
Eur Respir J. 2015 Aug;46(2):486-94
pubmed: 25745053
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Chest. 2013 Mar;143(3):814-824
pubmed: 23460159
J Pathol. 2010 Sep;222(1):52-63
pubmed: 20629113
Pharmacology. 2016;97(3-4):114-25
pubmed: 26734728
J Virol. 2006 Oct;80(19):9798-810
pubmed: 16973584
J Mol Histol. 2005 Feb;36(1-2):119-29
pubmed: 15704006
Am J Respir Crit Care Med. 2000 Dec;162(6):2213-7
pubmed: 11112140
Thorax. 2019 May;74(5):506-511
pubmed: 30723182
J Virol. 2000 Jun;74(11):4949-56
pubmed: 10799568
Expert Opin Investig Drugs. 2014 Jul;23(7):893-910
pubmed: 24766571
J Nucl Med. 2013 Dec;54(12):2146-52
pubmed: 24167080
Eur Respir J. 2015 May;45(5):1382-92
pubmed: 25504994
Cancer Res. 2007 Jun 15;67(12):5889-95
pubmed: 17575158
Exp Lung Res. 2015 Mar;41(2):57-73
pubmed: 25514507
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
J Nucl Med. 2017 Feb;58(2):201-207
pubmed: 28082432
SLAS Discov. 2017 Sep;22(8):962-973
pubmed: 28414923
Biochim Biophys Acta. 2013 Jul;1832(7):891-6
pubmed: 23046811
J Nucl Med Technol. 2018 Jun;46(2):136-143
pubmed: 29438002
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
pubmed: 17519979
Eur Respir J. 2011 Apr;37(4):743-6
pubmed: 21454891

Auteurs

Pauline T Lukey (PT)

GlaxoSmithKline Research and Development, Brentford, UK. paulinelukey@target2treatment.com.
Target to Treatment Consulting Ltd, Stevenage BioScience Catalyst, Stevenage, SG1 2FX, UK. paulinelukey@target2treatment.com.

Christopher Coello (C)

Invicro LLC, London, UK.

Roger Gunn (R)

Invicro LLC, London, UK.

Christine Parker (C)

GlaxoSmithKline Research and Development, Brentford, UK.

Frederick J Wilson (FJ)

GlaxoSmithKline Research and Development, Brentford, UK.

Azeem Saleem (A)

Invicro LLC, London, UK.

Nadia Garman (N)

GlaxoSmithKline Research and Development, Brentford, UK.

Maria Costa (M)

GlaxoSmithKline Research and Development, Brentford, UK.

Stuart Kendrick (S)

GlaxoSmithKline Research and Development, Brentford, UK.

Mayca Onega (M)

Invicro LLC, London, UK.

Arthur R Kang'ombe (AR)

GlaxoSmithKline Research and Development, Brentford, UK.

Allan Listanco (A)

Invicro LLC, London, UK.

James Davies (J)

Invicro LLC, London, UK.

Joaquim Ramada-Magalhaes (J)

Invicro LLC, London, UK.

Sara Moz (S)

Invicro LLC, London, UK.

William A Fahy (WA)

GlaxoSmithKline Research and Development, Brentford, UK.

Toby M Maher (TM)

NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.
Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK.

Gisli Jenkins (G)

National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK.

Jan Passchier (J)

Invicro LLC, London, UK.

Richard P Marshall (RP)

GlaxoSmithKline Research and Development, Brentford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH